Eisai To Produce Antibody Testing Agents In U.S. For FY2013 Trials
This article was originally published in PharmAsia News
Executive Summary
Eisai said it expects to begin U.S. production of antibody testing agents to be used in fiscal 2013 trials, beginning with producing supplies for as many as seven trials a year.
You may also be interested in...
Dainippon, SanBio Call Time On Stroke Cell Therapy Alliance
Japanese companies agree to discontinue regenerative cell therapy pact after high-profile Phase II failure, but SanBio will move ahead with development and Dainippon will hold onto ex-partner stake for now.
Strides Targets $200-400m From Generic Injectables In Mid-Term
Strides has set a sales target of $200-400m for Stelis’s generic injectables business in two to four years as part of its plan to reach $800m in total revenues in four years. Meanwhile, Stelis’s Rh-teriparatide for osteoporosis and sodium hyaluronate for osteoarthritis await Phase III incremental studies in the US.
Abbott Readying Vildagliptin ER In India Amid Price Competition
Abbott is developing an extended release version of vildagliptin in India, adding a new dimension to the market dynamics for the DPP-4 inhibitor, which has seen a key patent expire. Sustained release vildagliptin products from Wockhardt and Synokem also appear to be in the works.
Need a specific report? 1000+ reports available
Buy Reports